The Beauty Health Company (NASDAQ:SKIN) Receives Consensus Rating of “Hold” from Brokerages

The Beauty Health Company (NASDAQ:SKIN) has been given a consensus rating of “Hold” by the eight research firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and one has given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $2.42.

SKIN has been the subject of a number of research reports. Jefferies Financial Group restated a “hold” rating and set a $1.60 target price on shares of Beauty Health in a research note on Wednesday, January 14th. TD Cowen decreased their price target on shares of Beauty Health from $1.65 to $1.50 and set a “hold” rating on the stock in a research note on Monday, March 16th. Benchmark reissued a “hold” rating on shares of Beauty Health in a report on Friday, March 13th. Zacks Research upgraded shares of Beauty Health from a “strong sell” rating to a “hold” rating in a research report on Monday, March 16th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $1.50 price objective on shares of Beauty Health in a report on Friday, March 13th.

Institutional Trading of Beauty Health

Several institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio bought a new position in Beauty Health during the 3rd quarter worth $26,000. Franklin Resources Inc. acquired a new stake in shares of Beauty Health during the third quarter worth $31,000. Zacks Investment Management bought a new stake in shares of Beauty Health in the third quarter valued at about $35,000. Ameriprise Financial Inc. bought a new stake in shares of Beauty Health in the third quarter valued at about $38,000. Finally, Atom Investors LP acquired a new position in shares of Beauty Health in the fourth quarter valued at about $29,000. 93.26% of the stock is currently owned by institutional investors.

Beauty Health Stock Down 2.6%

SKIN stock opened at $1.13 on Tuesday. Beauty Health has a 1-year low of $0.78 and a 1-year high of $2.69. The business’s 50 day simple moving average is $1.24 and its 200 day simple moving average is $1.48. The company has a current ratio of 1.66, a quick ratio of 1.40 and a debt-to-equity ratio of 3.94. The firm has a market capitalization of $144.08 million, a PE ratio of -5.65 and a beta of 1.20.

Beauty Health (NASDAQ:SKIN) last announced its quarterly earnings results on Thursday, March 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.01. Beauty Health had a negative return on equity of 15.40% and a negative net margin of 3.16%.The business had revenue of $82.37 million during the quarter, compared to the consensus estimate of $78.07 million. As a group, research analysts anticipate that Beauty Health will post -0.25 EPS for the current year.

About Beauty Health

Beauty Health Company (NASDAQ: SKIN) is a U.S.-based consumer wellness and beauty enterprise that integrates device-based and product-based offerings across skin, body and hair wellness categories. The company operates a portfolio of established brands that blend professional and at-home solutions, focusing on innovative formulations and technologies to address a range of beauty and self-care needs. Through its proprietary e-commerce platforms and strategic retail partnerships, Beauty Health seeks to deliver premium experiences and tangible results to a global customer base.

Beauty Health’s brand portfolio includes Sol de Janeiro, known for its award-winning Brazilian Bum Bum Cream body care collection; Elemis, a U.K.-originated professional skin care line distributed in spas and skincare clinics; NuFACE and Dermaflash, two at-home beauty device brands specializing in microcurrent facial toning and gentle exfoliation respectively; and Nutrafol, a legal-strength hair wellness supplement clinically designed to support hair growth.